Knott David M Jr Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Knott David M Jr increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 15.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 440,000 shares of the biotechnology company’s stock after purchasing an additional 58,000 shares during the period. BioCryst Pharmaceuticals makes up 1.2% of Knott David M Jr’s portfolio, making the stock its 15th largest holding. Knott David M Jr’s holdings in BioCryst Pharmaceuticals were worth $3,309,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in BCRX. Venturi Wealth Management LLC purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $46,000. R Squared Ltd purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth about $48,000. KBC Group NV boosted its position in BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares during the period. Raymond James Financial Inc. purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $80,000. Finally, Quantinno Capital Management LP bought a new position in BioCryst Pharmaceuticals in the 3rd quarter worth about $82,000. 85.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on BCRX shares. Evercore ISI boosted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Wedbush started coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price for the company. Needham & Company LLC lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, JMP Securities reissued a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Down 4.6 %

NASDAQ:BCRX opened at $7.50 on Tuesday. The firm has a 50 day moving average of $8.18 and a 200 day moving average of $7.82. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $9.50. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -12.29 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. During the same period last year, the firm earned $0.28 earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% on a year-over-year basis. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.